Cadila Pharmaceuticals celebrates biggest scientific conclave ‘IAMICON’

Excelsior Correspondent
JAMMU, Nov 14: Cadila Pharmaceuticals Limited organised country’s biggest-ever scientific conclave-Indravadan Ambalal Modi Innovation Conclave (IAMICON) here to celebrate innovation and excellence in the Pharmaceuticals and Life Sciences sector.
Covering 50 cities across India, IAMICON 2014 will focus on advances in the treatment of Tuberculosis and Cardiovascular diseases.
Dr Varsha Koul, Dr Arjun Singh, Dr Nikhil Mahajan (All MD, Medicine), Gold Medalist from Government Medical College this year, was conferred the ‘Indravadan Ambalal Modi Academic Excellence Award’, which was presented by chief guest Dr Ghanshyam Dev Gupta.
Dr Mohan Lal was Chairperson for the sessions on ‘Cardiovascular Risk Management’ and ‘Recent Advancements in Tuberculosis’.
Dr Rajiv Modi, Chairman and Managing Director, Cadila Pharmaceuticals Limited said, “India’s pharmaceuticals sector has creditable contribution in providing affordable medicines to patients in India and across the globe.
“There have been bright sparks of innovation in our country, which have not received due attention. By showcasing such efforts every year and promoting the spirit of Indian innovation, IAMICON seeks to pay eternal tribute to our Founder-Chairman Shri Indravadan Ambalal Modi, the legendary Medicine Man of India”, he added.
Besides the latest updates in medical science, IAMICON 2014 will simultaneously spotlight the work of some eminent practitioners who will focus on advancements in treating TB and Cardiovascular Diseases. Through the ‘Indravadan Ambalal Modi Academic Excellence Awards’, IAMICON will also felicitate and encourage bright doctors with excellent academic performance in their post-graduate medical studies,” revealed Dr Modi.
He added that the IAMICON platform will also be used to spread the message of eradicating Tuberculosis from India and is committed to support Government of India’s ‘TB-Mission 2020’.
Cadila Pharmaceuticals Limited is among the few companies worldwide that have continued to invest in R&D to eliminate this deadly disease.